Exclusive Webinar: Treatment of Lung Cancer | 2020 ASCO Highlights

Meeting/Webinar Banner 01
Overview

This webinar will synthesize lung cancer research presented at the virtual ASCO meeting May 29-31, 2020.  It will address physicians need to keep abreast of current research and future trends to inform clinical practice.

Dr. Chandra Belani will moderate the program and lead the discussion and question and answer session following presentations by Taofeek Owonikoko, MD and Melissa Johnson, MD.  

Dr. Owonikoko will review Small Cell Lung Cancer (SCLC), locally advanced non-small cell lung cancer (NSCLC) and Mesothelioma.  Dr. Johnson will review metastatic NSCLC.

Date
Jul 31, 2020 -
Jul 31, 2020
Location

Online

This webinar will synthesize lung cancer research presented at the virtual ASCO meeting May 29-31, 2020.  It will address physicians need to keep abreast of current research and future trends to inform clinical practice.

Dr. Chandra Belani will moderate the program and lead the discussion and question and answer session following presentations by Taofeek Owonikoko, MD and Melissa Johnson, MD.  

Dr. Owonikoko will review Small Cell Lung Cancer (SCLC), locally advanced non-small cell lung cancer (NSCLC) and Mesothelioma.  Dr. Johnson will review metastatic NSCLC.

  • Identify recent data impacting the overall management of lung cancer patients;
  • Recognize new and evolving developments in standard treatment paradigms;
  • Discuss the status of ongoing and future clinical trials

Speaker Disclosure Information

Melissa Johnson

Consultant: Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, EMD Serono, Roche/Genentech, GlaxoSmithKline, Gritstone Oncology, Incyte, Janssen, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, WindMIL Therapeutics - All payment made to the institution, not Dr. Johnson

Contracted/ Supported Research Grant: Abbvie, Acerta, Adaptimmune, Amgen, Array, Apexigen, AstraZeneca, Atreca, BeiGene, BerGenBio, Birdie/Seven and Eight Biopharmaceuticals, Boehringer Ingelheim, Calithera, Checkpoint Therapeutics, Corvus Pharmaceuticals, Cytmox, Daiichi Sankyo, Dynavax Technologies, Eli Lilly, EMD Serono, Roche/Genentech, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics,  Immunocore, Incyte, Janssen, Merck, Mirati, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron, Sanofi, Shattuck Labs, Stem CentRx, Synadax, Takeda, Tarveda, University of Michigan, WindMIL Therapeutics, TCR2 Therapeutics, Arcus, Ribon Therapeutics, Rubius Therapeutics, Tmunity Therapeutics - All payment made to the institution, not Dr. Johnson Consultant (spouse): Otsuka

 

Taofeek Owonikoko

Advisory Board: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly,  Amgen,  AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Bayer

Contracted/ Supported Research Grant: Novartis; Astellas Pharma, Bayer, StemCentRx, Regeneron, AstraZeneca/MedImmune,  Abbvie, G1 Therapeutics, Bristol-Myers, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck

Ownership/Stock interest: Cambium Oncology

 

Chandra Belani

Speaker’s Bureau: Genentech, Takeda 

For any inquiries, please contact [email protected].

This webinar will synthesize lung cancer research presented at the virtual ASCO meeting May 29-31, 2020.  It will address physicians need to keep abreast of current research and future trends to inform clinical practice.

Dr. Chandra Belani will moderate the program and lead the discussion and question and answer session following presentations by Taofeek Owonikoko, MD and Melissa Johnson, MD.  

Dr. Owonikoko will review Small Cell Lung Cancer (SCLC), locally advanced non-small cell lung cancer (NSCLC) and Mesothelioma.  Dr. Johnson will review metastatic NSCLC.

  • Identify recent data impacting the overall management of lung cancer patients;
  • Recognize new and evolving developments in standard treatment paradigms;
  • Discuss the status of ongoing and future clinical trials

Speaker Disclosure Information

Melissa Johnson

Consultant: Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, EMD Serono, Roche/Genentech, GlaxoSmithKline, Gritstone Oncology, Incyte, Janssen, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, WindMIL Therapeutics - All payment made to the institution, not Dr. Johnson

Contracted/ Supported Research Grant: Abbvie, Acerta, Adaptimmune, Amgen, Array, Apexigen, AstraZeneca, Atreca, BeiGene, BerGenBio, Birdie/Seven and Eight Biopharmaceuticals, Boehringer Ingelheim, Calithera, Checkpoint Therapeutics, Corvus Pharmaceuticals, Cytmox, Daiichi Sankyo, Dynavax Technologies, Eli Lilly, EMD Serono, Roche/Genentech, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics,  Immunocore, Incyte, Janssen, Merck, Mirati, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron, Sanofi, Shattuck Labs, Stem CentRx, Synadax, Takeda, Tarveda, University of Michigan, WindMIL Therapeutics, TCR2 Therapeutics, Arcus, Ribon Therapeutics, Rubius Therapeutics, Tmunity Therapeutics - All payment made to the institution, not Dr. Johnson Consultant (spouse): Otsuka

 

Taofeek Owonikoko

Advisory Board: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly,  Amgen,  AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Bayer

Contracted/ Supported Research Grant: Novartis; Astellas Pharma, Bayer, StemCentRx, Regeneron, AstraZeneca/MedImmune,  Abbvie, G1 Therapeutics, Bristol-Myers, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck

Ownership/Stock interest: Cambium Oncology

 

Chandra Belani

Speaker’s Bureau: Genentech, Takeda 

For any inquiries, please contact [email protected].

Share

Interested in advertising and exhibit opportunities?